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Abstract 
Background: Obesity is a known risk factor for colon cancer, the second leading cause of cancer 
death in the United States. Excess visceral adipose tissue (VAT) associated with obesity 
stimulates pro-inflammatory and pro-tumorigenic signaling pathways that increases the risk for 
colon cancer. In this study we examine whether weight loss and/or treatment with the non-
steroidal anti-inflammatory drug sulindac reduces obesity-associated tumor growth in a mouse 
model of colon tumorigenesis. 
 
Methods: 10-week old male FVB mice (n=130) were given a chemical carcinogen, 
azoxymethane (10 mg/kg i.p.), for 5 weeks. Afterwards, the mice were randomized to a control 
(10% kcal from fat) or diet-induced obesity (DIO, 60% kcal from fat) diet for 15 weeks. 
Following an interim sacrifice of 5 mice/group, the DIO mice were further randomized to 
continue a DIO diet or switch to a control diet to induce weight loss and become formerly obese 
mice (FOb). Within each diet group (control, DIO, FOb) half the mice were randomized to 
receive sulindac supplementation (140 ppm in the diet). Eight weeks later, all mice were 
euthanized and tissues collected for analysis. Colon tumor gene expression was analyzed via 
microarray. 
 
Results: The DIO mice, compared to controls, had significantly greater final body weight and 
body fat levels (P<0.05), while FOb mice had intermediate levels of adiposity. Treatment with 
sulindac did not affect final body weight or body fat percentage compared to groups that did not 
receive treatment. At interim sacrifice, DIO mice had a 2-fold greater tumor incidence and a 10-
fold greater tumor burden compared to control mice. Across all groups, sulindac reduced tumor 
incidence, and in DIO and control mice, but not FOb mice, sulindac significantly reduced tumor 
burden (P<0.05). Several serum cytokines, including IL-6, CXCL1, VEGF, MCP-1, and G-CSF, 
were significantly elevated in DIO mice without sulindac treatment compared to control mice 
(P<0.05), but did not differ between FOb and control mice. Sulindac treatment significantly 
reduced serum levels of these proteins in DIO mice (P<0.05). Several adipokines, including 
leptin and PAI-1, were significantly increased in DIO mice in comparison to control and FOb 
mice (P<0.05). Sulindac treatment did not significantly reduce serum levels of these hormones in 
any of the diet groups. Tumor expression of matrix metalloproteinases and several genes 
involved in focal adhesion pathways was significantly higher in DIO mice versus the FOb and 
DIO + sulindac mice (P<0.05). Ccl21 expression was significantly increased by sulindac 
treatment in DIO mice (P<0.05) but not affected by weight loss. 
 
Conclusions: Weight loss and sulindac treatment completely reversed the effects of obesity on 
colon tumorigenesis, the latter without any change in adiposity. Tumoral gene expression 
suggests that these two interventions share some common anti-tumor mechanisms, but also may 
act through additional mechanisms specific to each intervention. Our findings indicate that 
research regarding the effects of NSAID treatment on colon cancer risk and/or progression in 
obese patients is warranted, especially in those who are unable to achieve moderate weight loss.  
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Introduction 
Colon Cancer Prevalence and Treatment 
 Colon cancer is the second most common cause of cancer death in the United States1 and 
is characterized by the abnormal proliferation of cells in the colon. In 2017, there was an 
estimated 95,520 new cases of colon cancer with nearly equal distribution of incidence between 
men and women.2 Since the 1980s, colon cancer survival rates have been rising due to increased 
awareness and early detection of polyps3. Current treatment for colon cancer is largely based on 
the stage of cancer, with earlier stages of cancer treated with polyp removal surgery and later 
stages using chemotherapy. If chemotherapy is used, FOLFOX (folinic acid, fluorouracil, and 
oxaliplatin) or CapeOx (capecitabine and oxaliplatin) are the most common treatment regimens4. 
The lifetime risk of developing colon cancer in men and women is approximately 4.5%, however 
this risk can increase with factors such as age, family history, and diet3.  
Impact of Obesity on Colon Cancer 
 Obesity is a known risk factor for a number of cancers5 and can increase risk of 
developing colorectal cancer by 30% compared to individuals of normal weight, especially in 
men6. While there is an association between increased risk of colon cancer and increased body 
mass index (BMI), research suggests waist circumference is a more consistent risk factor, 
possibly partially independent of BMI7. The link between abdominal obesity and colon cancer 
suggests adipocyte hypertrophy and associated aberrant metabolic and inflammatory signaling in 
the colon-adjacent visceral adipose tissue (VAT) may be an intermediary in obesity-associated 
colon tumor growth.  
The onset of obesity can cause chronic low-grade inflammation and adipocyte 
dysfunction. As an endocrine organ, adipose tissue releases both pro-inflammatory and anti-
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inflammatory hormones known as adipokines. With obesity, adipose tissue modification can lead 
to malfunction of adipokine secretion as well as changes in the number, size, and phenotype of 
adipocytes8. Dysregulation of adipose tissue endocrine function and inflammation leads to a 
systemic inflammatory response and associated comorbidities of obesity11.  
Through adipocyte death, which increases in adipocyte hypertrophy, white adipose tissue 
(WAT) macrophages scavenge for cell debris and create the appearance of ‘crown-like 
structures’ (CLS) in adipose tissue9. With time, activation of receptors on the macrophages and 
adipocytes can induce pro-inflammatory cytokine and chemokine release leading to further tissue 
remodeling and activation of the nuclear factor kappa-light-chain-enhancer of activated B cells 
(NFκB) pathway important for carcinogenesis 10, 14. The pro-inflammatory proteins released 
during obesity include interleukin (IL)-6, tumor necrosis factor (TNF)-α, monocyte 
chemoattractant protein (MCP)-1, leptin, and resistin8. These proteins, as well as other 
adipokines and cytokines, may promote the production of excess reactive oxygen species (ROS) 
within the colon, leading to DNA mutations and tumor initiation13. Furthermore, production of 
anti-inflammatory and anti-tumor adipokines, like adiponectin, is downregulated in this process. 
This change in metabolism and the hypoxic environment of excess adipose tissue can facilitate 
pro-tumorigenic conditions and activate signals used to promote cancer cell survival, 
proliferation, and migration12. 
Sulindac and Colon Cancer 
 A strong association between colon cancer risk and pro-inflammatory signaling has 
previously been established, and research demonstrates that the use of non-steroidal anti-
inflammatory drugs (NSAIDs) is associated with decreased incidence and polyp formation in 
colon cancer15-17. One type of NSAID, sulindac, has been investigated as a chemotherapeutic 
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treatment for colon and other cancers. This drug is especially known for its pro-apoptotic and 
growth inhibitory activity and its ability to concentrate in the colonic epithelium, contributing to 
its efficacy in colon cancer18-19.  
The mechanism through which sulindac targets cancer cells stems from its ability to 
inhibit both COX1 and COX2 pathways, which can promote tumor proliferation19, as well as its 
COX-independent anti-tumor mechanisms20. Conventional NSAIDs, which solely target COX-
dependent pathways, can be dangerous with prolonged use because they can lead to 
gastrointestinal tract bleeding, kidney failure, and cardio-toxicity due to prostaglandin 
inhibition20. Sulindac’s ability to further suppress tumor growth via COX-independent pathways, 
such as induction of EGR-1 protein expression, downregulation of EGFR signaling, and 
protection from E-cadherin loss, is one reason for its investigation as a cancer treatment20. Given 
that sulindac acts through multiple anti-tumor mechanisms, it may be possible to achieve a 
response with a relatively smaller dose that does not induce the typical NSAID side effects. 
These studies suggest that reducing inflammatory signaling via sulindac treatment may be an 
effective strategy for decreasing obesity-induced colon tumor growth and incidence. However, 
further research is still necessary to fully understand the cell signaling pathways sulindac targets 
to reduce cancer progression. 
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Goal and Hypotheses 
 The primary goal of this study was to investigate whether weight loss and/or NSAID 
treatment reduces obesity-associated tumor growth in a mouse model of colon tumorigenesis. 
This was accomplished through four specific aims. The first was to characterize the impact of 
sulindac treatment on body weight, body composition, and serum metabolic hormone levels in 
obese and lean mice. We predicted that sulindac would not affect body weight and body 
composition, but may reduce some metabolic hormone levels. 
 Our second specific aim was to assess the effects of sulindac treatment in obese and lean 
mice and weight loss in obese mice on colon tumor incidence, multiplicity, and size. Due to the 
research indicating that sulindac reduces colon tumorigenesis, we hypothesized that colon tumor 
incidence, multiplicity, and size would diminish in groups treated with sulindac, including the 
obese mice, and also with weight loss in the formerly obese mice. 
 The third specific aim was to determine the effects of sulindac treatment and obesity 
reversal on systemic, colon tissue, and visceral adipose tissue inflammation by measuring 
markers of inflammation in the serum and tissues. Given that sulindac is an NSAID, we 
anticipated reduced levels of serum inflammatory cytokines in groups treated with the drug and 
also in formerly obese mice. 
 Our final aim was to determine and characterize the effects of sulindac treatment and 
obesity reversal on gene expression in tumors by analyzing microarray data. We hypothesized 
that the expression of genes with anti-tumorigenic activity would be increased and genes with 
pro-tumorigenic activity decreased in the mice treated with sulindac and in formerly obese mice 
that experienced weight loss. 
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Methods 
Animal study design:  
10-week old male FVB mice (n=130) were given a chemical carcinogen, azoxymethane 
(10 mg/kg i.p.), for 5 weeks. Afterwards, the mice were randomized to a control (10% kcal from 
fat) or diet-induced obesity (DIO, 60% kcal from fat) diet for 15 weeks. Following an interim 
sacrifice of 5 mice/group, the DIO mice were further randomized to continue a DIO diet or 
switch to a control diet to induce weight loss and become formerly obese mice (FOb). Within 
each diet group (control, DIO, FOb) half the mice were randomized to receive sulindac 
supplementation (140 ppm in the diet). Eight weeks later, all mice were sacrificed by carbon 
dioxide euthanasia and cervical dislocation. The samples collected from the mice during the 
study included serum, colon rolls (paraffin-embedded), tumor (flash-frozen), normal colon 
epithelium (flash-frozen), mesenteric adipose tissue (paraffin-embedded and flash-frozen), and 
fecal samples (flash-frozen) at baseline, before diet switch, and endpoint of the study. 
Body Weight and Fat Composition Analysis: 
 Body weight of mice was taken at baseline and then weekly until euthanization. Body 
composition was measured using dual energy X-ray absorption (DEXA) after euthanization. 
Tumor Incidence, Multiplicity, and Size Analysis: 
Investigator enumerated the colon tumors for each mouse at interim sacrifice and at the 
endpoint of the study. Digital calipers were used to measure two dimensions of each tumor to 
calculate the total tumor cross-sectional area. 
Serum Cytokine Analysis: 
Serum cytokines were analyzed using Bio-Plex Multiplex Immunoassay on a Bio-Plex® 
Magpix Multiplex Reader (Bio-Rad). 
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Serum Metabolic Hormone Level Analysis: 
Serum metabolic hormones were analyzed using Bio-Plex Multiplex Immunoassay on a 
Bio-Plex® Magpix Multiplex Reader (Bio-Rad). Serum IGF-1 was measured via a Mouse 
Magnetic Luminex Screening Assay (R&D Systems). 
Microarray Analysis: 
 First, RNA isolation was performed on flash-frozen colon tumors using TRIzol Reagent 
(Sigma-Aldrich) according to manufacturer’s instructions. RNA integrity was assessed on an 
Agilent 2100 Bioanalyzer, and RNA was analyzed via Clariom S Microarray (Affymetrix) by 
UNC’s Functional Genomics Core. Genes of interest from the microarray were then validated by 
quantitative RT-PCR. RNA was reverse-transcribed to cDNA using MultiScribe Reverse 
Transcriptase (ThermoFisher Scientific), then analyzed using Taqman™ Gene Expression 
Assays (Applied Biosystems) on a ViiA™7 RT-PCR System (Applied Biosystems). 
Statistical Analysis: 
 Animal study data is presented as mean ± SD. All data except the microarray analysis 
was analyzed by two-way ANOVA, followed by Tukey’s post hoc test, using GraphPad Prism 7 
software. Microarray data was analyzed using the Transcriptome Analysis Console (TAC) 
software from Life Technologies. In all figures, different letters indicate significant differences, 
and P<0.05 was considered statistically significant.   
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Results 
Body Weight and Composition Analysis: 
Each diet group (Control, DIO, FOb) had significantly different final body weights in 
comparison to each other (Figure 1A, 1B). Specifically, DIO mice, compared to controls, had 
significantly greater body weight (P<0.0001), while FOb mice had intermediate levels of final 
body weights that were significantly different from both Control (P=0.006) and DIO (P<0.0001) 
mice. However, sulindac treatment did not significantly affect body weight within each diet 
group (Figure 1A, 1B). Body fat percentage was significantly different between DIO mice and 
control mice (P<0.0001) that received the same treatment, but sulindac treatment within each 
diet group did not significantly affect body composition (Figure 1C). Body fat percentage of FOb 
mice did not significantly differ from control groups, but did differ from DIO mice with sulindac 
treatment (P=0.0026; Figure 1C).  
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Figure 1. (A) Body weight over time. (B) Body fat percent. (C) Final body weights. Different 
letters indicant significant differences, P < 0.05.  
 
Tumor Incidence, Multiplicity, and Size Analysis: 
At interim sacrifice, DIO mice had a non-significant 2-fold greater incidence of tumor 
compared to control mice (Figure 2A). At the end of the study, sulindac reduced tumor incidence 
across all groups (P=0.014; Figure 2B). At interim sacrifice, DIO mice had a non-significant 10-
fold greater tumor multiplicity compared to control mice (Figure 2C). Sulindac significantly 
reduced tumor multiplicity in both control (P=0.044) and DIO (P<0.0001) mice, but not FOb 
mice (Figure 2D). Tumor cross-sectional area was significantly increased in DIO mice relative to 
all other groups (P<0.01 for all comparisons, Figure 2E).  
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Figure 2. (A) Tumor incidence at interim sacrifice (sac). (B) Final tumor incidence. (C) Tumor 
burden at interim sac. (D) Final tumor burden. (E) Final total tumor cross-sectional area. 
Different letters indicant significant differences, P < 0.05.  
 
Serum Cytokines Analysis: 
  Serum levels of interleukin 6 (IL-6), vascular endothelial growth factor (VEGF), 
monocyte chemoattractant protein-1 (MCP-1), chemokine (C-X-C) ligand 1 (CXCL1), and 
granulocyte colony-stimulating factor (G-CSF) were significantly elevated in DIO mice without 
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sulindac treatment in comparison to control mice with and without sulindac treatment (P<0.05 
for all comparisons; Figure 3A-E). Serum levels of all cytokines measured did not differ between 
FOb and control mice that received the same treatment (Figure 3A-J). Sulindac treatment 
significantly reduced serum levels of IL-6, VEGF, MCP-1, CXCL1, G-CSF, and IL-1β in DIO 
mice (P<0.05 for all comparisons; Figure 3A-F). In control and FOb mice groups, sulindac 
treatment non-significantly reduced all serum cytokine levels (Figure 3A-J) with the exception of 
Interferon gamma (IFNγ), which exhibited a significant decrease with sulindac treatment in the 
control group (P=0.0186; Figure 3G) and CXCL1, which was slightly higher with sulindac 
treatment in the control group (Figure 3D). Treatment with sulindac in DIO mice reduced serum 
cytokines to a level that did not significantly differ from control and FOb groups treated with 
sulindac (Figure 3A-J). There were no significant differences across all groups in serum cytokine 
levels of IL-17 and IL-10 (Figure 3H-I).  
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Figure 3. Serum levels of (A) IL-6, (B) VEGF, (C) MCP-1, (D) CXCL1, (E) G-CSF, (F) IL-1β, 
(G) IFNγ, (H) IL-17, (I) IL-10, (J) TNFα. Different letters indicate significant differences, P < 
0.05. 
Serum Metabolic Hormone Analysis:  
There was a significant increase in leptin and insulin-like growth factor 1 (IGF-1) levels 
in all DIO mice compared to all control mice (P<0.05 for all comparisons; Figure 4A-B). Serum 
levels of adiponectin, glucagon-like peptide-1 (GLP-1), glucagon, ghrelin, insulin, gastric 
inhibitory polypeptide (GIP), plasminogen activator inhibitor-1 (PAI-1), and resistin were not 
significantly different between DIO mice and control mice (Figure 4C-J). Glucagon, ghrelin, 
insulin, GIP, and resistin were not significantly different between DIO mice and FOb mice that 
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received the same treatment (Figure 4E-H, J). Leptin levels were significantly increased in DIO 
mice compared to control and FOb mice (P<0.05 for all comparisons; Figure 4A), and there was 
a significant increase in leptin:adiponectin ratio in DIO mice compared to the other groups 
(P<0.05 for all comparisons; Figure 4K). Sulindac treatment did not significantly change serum 
levels of leptin, IGF-1, adiponectin, GLP-1, ghrelin, insulin, GIP, PAI-1, or resistin (Figure 4A-
D, F-J) within any of the diet groups with the exception of glucagon levels in DIO mice, which 
were significantly decreased with sulindac treatment (P=0.006, Figure 4E). There were no 
significant differences across any of the groups in serum hormone levels of insulin, GIP, and 
resistin (Figure 4G-H, J).  
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Figure 4. Serum levels of (A) Leptin, (B) Leptin, (C) Adiponectin, (D) GLP-1, (E) Glucagon, 
(F) Ghrelin, (G) Insulin, (H) GIP, (I) PAI-1, (J) Resistin, (K) Leptin:adiponectin ratio. Different 
letters indicate significant differences, P < 0.05. 
 
Microarray Analysis: 
Hierarchical clustering of the microarray data demonstrates that tumoral gene expression clusters 
by group (Figure 5). This data indicates that tumoral gene expression is linked to and varies by 
the diet and treatment received. 
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Figure 5.  Hierarchal clustering of gene expression. 
 
Analysis of tumoral gene expression by microarray revealed that in control and DIO mice 
there were significant differences in gene enrichment (P<0.05), primarily for metabolism-related 
pathways. We chose to further explore pathways that were associated with cancer progression, 
such as oxidative stress, estrogen metabolism, Keap1-Nrf2, and focal adhesion, which led to 
validation by qPCR of Nqo1 and Ngf gene expression (Table 1). When comparing DIO with 
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DIO+Sulindac mice, pathways of interest included matrix metalloproteinases, Keap1-Nrf2, 
chemokine signaling, and estrogen metabolism. This led to validation by qPCR of Mmp10, 
Mmp3, Mmp13, Ccl11, Ccl21, and Nqo1 gene expression (Table 2). Furthermore, when 
analyzing differences between DIO and FOb mice, significant pathways of interest involved in 
cancer progression included matrix metalloproteinases, focal adhesion, and TGF beta signaling, 
which led to validation through qPCR of Col1a2, Col5a2, Flt1, Fn1, Pgf, Zeb2, Tfgbr2, Mmp9, 
and Mmp12 (Table 3). Gene expression levels of the pro-inflammatory, pro-tumor cytokine Il11 
were also found to be significantly higher in DIO (P=0.0027) and Control (P=0.017) mice 
relative to DIO+Sulindac mice in our microarray analysis, so Il11 expression was validated by 
qPCR as well.   
 
Pathway Genes Upregulated Genes Downregulated P-value 
Oxidative Stress Nqo1 Mgst1 0.0017 
Adipogenesis genes  Lpl, Cebpd, Frzb 0.0028 
Retinol metabolism  Lpl, Rbp4 0.0031 
Alzheimers Disease  Lpl, Casp12 0.012 
Alanine and aspartate metabolism  Gad2 0.025 
Estrogen metabolism Nqo1  0.027 
Keap1-Nrf2 Nqo1  0.029 
Biogenic Amine Synthesis  Gad2 0.031 
Focal Adhesion-PI3K-Akt-
mTOR-signaling pathway 
Efna3 Ngf, Pfkfb3 0.032 
Statin Pathway  Lpl 0.042 
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Table 1. Top ten most significant pathways for Control vs. DIO mice. 
 
Pathway Genes Upregulated Genes Downregulated P-value 
Matrix Metalloproteinases Mmp10, Mmp3, 
Mmp13 
 0.00050 
Keap1-Nrf2  Gsta2, Nqo1 0.0025 
Endochondral Ossification Frzb, Mmp13, Plau  0.0046 
Spinal Cord Injury Gadd45a, Gja1 Tacr1 0.017 
Chemokine signaling pathway Gm13306, Ccl11 Ccl21a, Ccl21c 0.019 
Complement and Coagulation 
Cascades 
Serpind1, Plau  0.044 
Lung fibrosis Ccl11, Plau  0.047 
Heme Biosynthesis Alas2  0.047 
Alanine and aspartate metabolism Gad2  0.063 
Estrogen metabolism  Nqo1 0.068 
Table 2. Top ten most significant pathways for DIO vs. DIO+Sulindac mice. 
 
Pathway Genes Upregulated Genes Downregulated P-value 
Spinal Cord Injury Ptprz1, Mmp12, 
Mmp9, Pla2g5, Selp 
 0.00068 
XPodNet - protein-protein 
interactions in the podocyte 
expanded by STRING 
Trf, Ltbp1, Flt1, 
Ngf, Zeb2, Fn1, 
Csf1, Wif1, Sulf1, 
 0.00070 
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Angptl2, Tgfb3, 
Tcf21, Sparc, Nrp1, 
Tgfbr2 
PodNet: protein-protein 
interactions in the podocyte 
Wif1, Sulf1, 
Angptl2, Tgfb3, 
Tcf21, Sparc, Nrp1, 
Tgfbr2 
 0.0016 
Focal Adhesion Col1a2, Col5a2, 
Flt1, Fn1, Pgf 
Tesk2 0.0017 
TGF Beta Signaling Pathway Tgfbr2, Ltbp1, Zeb2  0.0055 
Focal Adhesion-PI3K-Akt-
mTOR-signaling pathway 
Col1a2, Col5a2, 
Fn1, Csf1, Pgf, Ngf, 
Flt1 
 0.0075 
Endochondral Ossification Pthlh, Frzb, Mmp9  0.0090 
Matrix Metalloproteinases Mmp9, Mmp12  0.017 
Inflammatory Response Pathway Col1a2, Fn1  0.018 
Prostaglandin Synthesis and 
Regulation 
Anxa5 Hpgd 0.019 
Table 3. Top ten most significant pathways for DIO vs. FOb mice. 
 
Sulindac treatment and weight loss significantly reduce relative mRNA levels for matrix 
metalloproteinase genes Mmp9, Mmp10, and Mmp13 compared to DIO mice (P<0.05 for all 
comparisons; Figure 6B-C,E) Additionally, sulindac treatment and weight loss non-significantly 
reduced relative mRNA levels of Mmp3 and Mmp12 (Figure 6A, D). Sulindac treatment 
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significantly increased relative mRNA levels for Ccl21 (P=0.0032, Figure 6G), while weight loss 
and sulindac treatment significantly reduced mRNA levels of Ccl11 compared to DIO mice 
(P<0.05 for all comparisons; Figure 6F). Relative mRNA levels for genes involved in the focal 
adhesion pathway, Col1a2, Col5a2, Csf1, Fn1, Pgf, and Ngf, were significantly reduced in the 
FOb mice compared to DIO mice (P<0.05 for all comparisons; Figure H-J, N, P, R). No 
significant differences between groups were seen in Il11, Zeb2, Flt1, and Tgfbr2 expression 
(Figure 5K-M, O). Nqo1 expression was significantly reduced in DIO relative to control mice 
(P=0.0480), but did not significantly differ between FOb and DIO+Su mice (Figure 5Q).  
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Figure 6. Tumoral gene expression levels, measured by qPCR, of (A) Mmp3, (B) Mmp9, (C) 
Mmp10, (D) Mmp12, (E) Mmp13, (F) Ccl11, (G) Ccl21, (H) Col1a2, (I) Col5a2, (J) Csf1, (K) 
Il11, (L) Zeb2, (M) Flt1, (N) Fn1, (O) Tfgbr2, (P) Pgf, (Q) Nqo1, (R) Ngf. Different letters 
indicate significant differences, P < 0.05. 
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Discussion 
 This study aimed to understand whether the tumor-promoting effects of obesity could be 
reversed by an NSAID and/or weight loss in a mouse model of colon cancer. The study produced 
substantial evidence indicating that moderate weight loss and treatment by sulindac both reverse 
the pro-tumor effects of obesity. There is evidence that weight loss and sulindac may reduce 
tumor growth through a decrease in matrix metalloproteinase and focal adhesion pathways. 
Matrix metalloproteinases are important regulators of tumor growth and contribute to 
extracellular remodeling, angiogenesis, cellular differentiation, proliferation and apoptosis. 
These zinc dependent endopeptidases work by degrading extracellular matrix (ECM) proteins 
that are used to prevent tumor invasion and metastasis21. In groups treated by sulindac and 
weight loss, gene expression of matrix metalloproteinases (Mmp3, Mmp9, Mmp10, Mmp12 and 
Mmp13) were reduced compared to the untreated obese mice, suggesting a decrease in MMP-
related tumor progression activity.  
Additionally, expression of genes used in focal adhesion pathways (Col1a2, Col5a2, 
Flt1, Fn1, Pgf, Csf1, Ngf) were also reduced in weight loss and drug treated groups compared to 
untreated obese mice. Focal adhesion pathways are activated during cancer development to allow 
signaling between cancer cells and the tumor microenvironment22. Cancer cells work with ECM 
proteins to form intracellular complexes named focal adhesions, which use signaling proteins to 
reorganize the cytoskeleton. This rearrangement in the tumor environment is important for tumor 
angiogenesis and metastasis, which enables cancer progression22. This reduction in focal 
adhesion-related genes in the tumors may be another mechanism by which sulindac and weight 
loss are able to reduce tumor growth. 
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However, weight loss and sulindac treatment also differentially affected tumor gene 
expression. Evidence for differences between the sulindac and weight loss-treated mice are 
especially apparent in the differences in Ccl21 gene expression. CCL21, also known as 
chemokine (C-C motif) ligand 21, is a chemokine that regulates cell recruitment and T-cell 
activation following localization of lymphocytes and stimulated dendritic cells23-24. In the 
literature, there is evidence that CCL21 is able to induce infiltration of immune cells into the 
tumor microenvironment and suppress the growth of the tumor by producing a tumor-specific 
immune response. In studies that sought to evaluate the prognostic significance of Ccl21 gene 
expression in colorectal cancer patients, results demonstrate that high expression of Ccl21 was an 
independent predictor of more favorable survival24. The data from our study demonstrate that 
Ccl21 gene expression is significantly increased in sulindac mice in comparison to the obese, 
control, and weight loss groups. This difference in gene expression is indicative not only of 
differences in the mechanisms by which sulindac and weight loss affect tumor progression, but 
also reveals a mechanism beyond changes in COX activity by which sulindac acts as an effective 
anti-tumor drug. 
Our data indicates that the manner by which sulindac inhibits tumor growth utilizes both 
COX dependent and independent pathways. Literature suggests that prostaglandin E2, a key pro-
inflammatory eicosanoid produced by COX-225, can induce expression of MMP926, which along 
with other metalloproteinases acts to enhance cancer progression. One reason for a decrease in 
metalloproteinase expression in sulindac mice without changes in adiposity levels is sulindac’s 
ability to inhibit the byproducts of COX pathways from forming. However, based on sulindac’s 
association with increased CCL21 levels, it is also evident that the drug is able to reduce tumor 
progression through COX independent pathways. For CCL21-induced signal transduction and 
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recruitment of dendritic cells to produce a tumor suppressing response, prostaglandin E2 is 
required27. Since prostaglandin E2 is a by-product of COX-2, there is evidence that sulindac 
treatment is also effective in reversing the pro-tumor effects of obesity through COX-
independent mechanisms. This finding particularly reveals sulindac’s versatility compared to 
other NSAIDs because it is able to act in a COX dependent and independent manner to inhibit 
the progression of colon cancer. 
 
Conclusions 
Moderate weight loss and sulindac treatment both completely reverse the effects of chronic 
obesity on colon tumorigenesis. Sulindac treatment reverses the effect of obesity independent of 
any change in adiposity. These two interventions may share some common anti-tumor 
mechanisms, but also have different treatment-specific effects based tumoral gene expression 
analysis. The findings suggest that research regarding the effects of NSAID treatment on colon 
cancer risk and/or progression in obese patients is warranted, especially in those who are unable 
to achieve moderate weight loss. 
 
Future Directions 
Future goals of study include determining the effects of sulindac treatement on visceral adipose 
tissue (VAT) inflammation by measuring the incidence of crown-like structures, and 
determining4/26/18 2:52 PM tumor grade and inflammation in the colon through tissue analysis 
by veterinary pathologist. We also aim to measure prostaglandin E2 in the blood and adipose 
tissue due to the results of our study.  
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